| Literature DB >> 34824993 |
Juan Pablo Forero1, Alexander Ferrera1, Jose Daniel Castaño2,3, Sergio Ardila4, Tanya Mesa4, Dean Hosgood1, Eugenio Ferro4.
Abstract
Background: Various multifactorial elements may contribute toward the urban and rural disparities in cardiovascular disease (CVD) risk, particularly among patients with psychiatric diseases. Objective: To investigate whether rural patients diagnosed and treated for Bipolar Disorder (BD) have different risk profiles and outcomes of CVD compared to urban (BD) patients.Entities:
Mesh:
Year: 2021 PMID: 34824993 PMCID: PMC8603855 DOI: 10.5334/aogh.3479
Source DB: PubMed Journal: Ann Glob Health ISSN: 2214-9996 Impact factor: 2.462
Demographic information comparing Rural Filadelfia Bipolar Disorder population with urban Bogota Bipolar Disorder Population. Comparison of age, sex, BMI, education, alcohol use, current tobacco use, family history, and non-psychiatric comorbid conditions.
|
| |||||||
|---|---|---|---|---|---|---|---|
| DEMOGRAPHIC CHARACTERISTICS | RURAL | URBAN | TOTAL | p-VALUE | |||
|
|
|
| |||||
| n | % OR AVG | n | % OR AVG | n | % OR AVG | ||
|
| |||||||
| Male | 46 | 36.8 | 92 | 36.8 | 138 | 36.8 | 1.0 |
|
| |||||||
| Age | 125 | 53.2 | 250 | 54.1 | 375 | 53.8 | 1.0 |
|
| |||||||
| BMI | 123 | 25.9 | 218 | 26.1 | 341 | 26.0 | 0.73 |
|
| |||||||
| Completed Education | 19 | 22.1 | 218 | 90.5 | 237 | 72.5 | 1.0 × 10–4 |
|
| |||||||
| Alcohol | 7 | 5.98 | 49 | 20.9 | 56 | 15.9 | 3.0 × 10–4 |
|
| |||||||
| Smoking | 24 | 20.5 | 84 | 33.6 | 108 | 29.4 | 0.015 |
|
| |||||||
| Psychiatric Family History | 27 | 24.6 | 156 | 43.5 | 183 | 50.8 | 1.0 × 10–4 |
|
| |||||||
| CVD Family History | 30 | 28.3 | 108 | 44.6 | 138 | 39.7 | 0.0042 |
|
| |||||||
| Pulmonary Conditions | 6 | 4.80 | 26 | 10.4 | 32 | 8.53 | 0.067 |
|
| |||||||
| GI Conditions | 34 | 27.2 | 36 | 9.60 | 70 | 18.7 | 0.0027 |
|
| |||||||
| Hypothyroidism | 8 | 6.40 | 55 | 22.0 | 63 | 16.8 | 1.0 × 10–4 |
|
| |||||||
Differences in psychiatric and non-psychiatric pharmacological treatment between rural (Filadelfia) and urban (Bogota) Bipolar Disorder populations in Colombia.
|
| |||||||
|---|---|---|---|---|---|---|---|
| PHARMACOLOGICAL TREATMENT | RURAL | URBAN | TOTAL | p-VALUE | |||
|
|
|
| |||||
| n | % | n | % | n | % | ||
|
| |||||||
| Valproic Acid | 84 | 67.2 | 115 | 46.0 | 199 | 53.1 | 1.0 × 10–4 |
|
| |||||||
| Lithium | 17 | 13.6 | 79 | 31.6 | 96 | 25.6 | 2.0 × 10–4 |
|
| |||||||
| Lamotrigine | 1 | 0.8 | 37 | 14.8 | 38 | 10.1 | 1.0 × 10–4 |
|
| |||||||
| Anticonvulsants | 13 | 10.4 | 22 | 8.80 | 35 | 9.33 | 0.62 |
|
| |||||||
| 1st Generation Anti-Psychotics | 17 | 13.6 | 116 | 46.4 | 133 | 35.5 | 1.0 × 10–4 |
|
| |||||||
| SSRIs | 52 | 41.6 | 71 | 28.4 | 123 | 32.8 | 1.0 × 10–2 |
|
| |||||||
| Atypical Antidepressants | 25 | 20.0 | 34 | 13.6 | 59 | 15.7 | 0.11 |
|
| |||||||
| 2nd Generation Anti-Psychotics | 47 | 37.6 | 224 | 89.6 | 271 | 72.3 | 1.0 × 10–4 |
|
| |||||||
| Lipid Drugs | 24 | 19.2 | 42 | 16.8 | 66 | 17.6 | 0.57 |
|
| |||||||
| Diabetes | 9 | 7.20 | 19 | 7.60 | 29 | 7.47 | 0.89 |
|
| |||||||
| Anti-Coagulants/Platelets | 8 | 6.40 | 8 | 3.20 | 16 | 4.27 | 0.15 |
|
| |||||||
| NSAIDs | 40 | 32.0 | 114 | 45.6 | 154 | 41.1 | 1.0 × 10–2 |
|
| |||||||
Comparison of overall Cardiovascular Disease morbidity, risk factors and profiles between rural (Filadelfia) and urban (Bogota) patients with Bipolar Disorder in Colombia.
|
| |||||||
|---|---|---|---|---|---|---|---|
| CVD MORBIDITY | RURAL | URBAN | TOTAL | p-VALUE | |||
|
|
|
| |||||
| n | % | n | % | n | % | ||
|
| |||||||
| Overall | 21 | 16.8 | 20 | 8.00 | 41 | 10.9 | 1.0 × 10–2 |
|
| |||||||
| CAD | 10 | 8.00 | 9 | 3.60 | 19 | 5.07 | 0.067 |
|
| |||||||
| PAD | 15 | 12 | 3 | 1.20 | 18 | 4.80 | 1.0 × 10–4 |
|
| |||||||
| CHF | 0 | 0 | 4 | 1.60 | 4 | 1.07 | 0.16 |
|
| |||||||
| Arrhythmia | 2 | 1.60 | 3 | 1.20 | 5 | 1.33 | 0.75 |
|
| |||||||
| Valvular | 0 | 0 | 1 | 0.40 | 1 | 0.26 | 0.48 |
|
| |||||||
| Stroke/TIA | 1 | 0.80 | 2 | 0.80 | 3 | 0.80 | 1.0 |
|
| |||||||
| CVD Risk Factors for FHS | |||||||
|
| |||||||
| SBP | 119 | 118 | 244 | 123 | 363 | 121 | 3.0 × 10–4 |
|
| |||||||
| Treatment for HTN | 39 | 31.2 | 58 | 23.2 | 97 | 25.9 | 0.095 |
|
| |||||||
| HTN | 38 | 30.4 | 45 | 18.0 | 83 | 22.1 | 0.0064 |
|
| |||||||
| Diabetes | 12 | 9.60 | 18 | 7.20 | 30 | 8.00 | 0.42 |
|
| |||||||
| Smoking | 24 | 20.5 | 84 | 33.6 | 108 | 29.4 | 0.015 |
|
| |||||||
| BMI >30 | 20 | 16.7 | 45 | 20.6 | 65 | 19.2 | 0.37 |
|
| |||||||
| Dyslipidemia | 55 | 44.0 | 30 | 12.0 | 85 | 22.7 | 1.0 × 10–4 |
|
| |||||||
| Estimated CV Risk Prediction | 95 | 9.72 | 206 | 11.3 | 301 | 10.8 | 0.15 |
|
| |||||||
| >20% 10 yr Risk of CVD | 13 | 13.7 | 42 | 20.4 | 55 | 18.3 | 0.16 |
|
| |||||||
Cardiovascular Disease (CVD) risk profile (>10% risk of CVD in 10 years), education, alcohol consumption, and psychiatric treatment for the rural (Filadelfia) Bipolar Disorder (BD) population when compared with an urban (Bogota) Bipolar Disorder population in Colombia.
|
| ||
|---|---|---|
| ODDS RATIO | 95% CONFIDENCE INTERVAL | |
|
| ||
| CVD Risk | 0.192 | 0.059–0.623 |
|
| ||
| Completed Education | 0.0120 | 0.003–0.045 |
|
| ||
| Alcohol Consumption | 0.191 | 0.032–1.135 |
|
| ||
| 1st Generation Anti-psychotics | 0.115 | 0.029–0.462 |
|
| ||
| 2nd Generation Anti-psychotics | 0.0460 | 0.013–0.156 |
|
| ||
| Valproic Acid | 1.957 | 0.611–6.274 |
|
| ||
| Lithium | 1.74 | 0.472–6.435 |
|
| ||
| Atypical Antidepressants | 1.21 | 0.272–5.382 |
|
| ||
| SSRI | 1.53 | 0.485–4.847 |
|
| ||
Risk profiles associated with <10% risk of Cardiovascular Disease (CVD) in 10 years compared to those with >10% risk of CVD in ten years, among Bipolar Disorder patients in Colombia. Lamotrigine was excluded in the rural population due to small sample size.
|
| ||||
|---|---|---|---|---|
| BOGOTA (URBAN) | FILADELFIA (RURAL) | |||
|
|
| |||
| ODDS RATIO | 95% CONFIDENCE INTERVAL | ODDS RATIO | 95% CONFIDENCE INTERVAL | |
|
| ||||
| Alcohol | 0.803 | 0.359–1.793 | 0.692 | 0.054–8.825 |
|
| ||||
| 1st Generation Anti-psychotics | 1.43 | 0.729–2.794 | 0.638 | 0.121–3.369 |
|
| ||||
| 2nd Generation Anti-psychotics | 1.64 | 0.542–4.957 | 1.07 | 0.371–3.081 |
|
| ||||
| Lithium | 1.22 | 0.58–2.583 | 1.35 | 0.3086.315 |
|
| ||||
| Valproic Acid | 0.521 | 0.264–1.03 | 0.820 | 0.244–2.763 |
|
| ||||
| TCA | 1.76 | 0.132–23.518 | 1.57 | 0.191–12.901 |
|
| ||||
| SSRI | 1.05 | 0.493–2.228 | 2.19 | 0.711–6.728 |
|
| ||||
| Atypical Antidepressants | 3.09 | 0.967–9.886 | 0.605 | 0.154–2.38 |
|
| ||||
| Lamotrigine | 1.81 | 0.699–4.7 | ||
|
| ||||
| Anticonvulsants | 1.08 | 0.358–3.236 | 1.39 | 0.226–8.563 |
|
| ||||
| Lipids Medications | 0.275 | 0.103–0.734 | 1.19 | 0.248–5.69 |
|
| ||||
| Anticoagulants | 0.295 | 0.038–2.303 | 2.42 | 0.196–29.871 |
|
| ||||
| NSAIDs | 0.707 | 0.63–1.39 | 0.248 | 0.077–0.798 |
|
| ||||
Comparison of unconditional regression models from Bipolar Disorder patients from rural Colombia (Filadelfia) and urban Colombia (Bogota). Modeling is based on patients with low risk profiles (<10% Cardiovascular disease risk in 10 years) when compared to patients with high risk profiles (>10% Cardiovascular disease risk in 10 years). Lamotrigine, TCA, Anticoagulant, and Diabetic Medications were excluded since these variables did not have sufficient variation in the data.
|
| ||||
|---|---|---|---|---|
| MODELING PROBABILITY FOR PATIENTS WITH BETTER RISK PROFILES | BOGOTA (URBAN) | FILADELFIA (RURAL) | ||
|
|
| |||
| ODDS RATIO | 95% CONFIDENCE INTERVAL | ODDS RATIO | 95% CONFIDENCE INTERVAL | |
|
| ||||
| Alcohol Consumption | 0.742 | 0.274–2.007 | 0.44 | 0.031–6.218 |
|
| ||||
| 1st Generation Anti-psychotics | 1.14 | 0.487–2.66 | 0.715 | 0.117–4.361 |
|
| ||||
| 2nd Generation Anti-psychotics | 0.558 | 0.118–2.635 | 1.14 | 0.299–4.352 |
|
| ||||
| Lithium | 0.857 | 0.333–2.201 | 3.14 | 0.299–4.352 |
|
| ||||
| Valproic Acid | 0.721 | 0.307–1.691 | 1.08 | 0.246–4.746 |
|
| ||||
| TCA | 0.753 | 0.038–15.047 | ||
|
| ||||
| SSRI | 0.902 | 0.352–2.308 | 1.20 | 0.306–4.678 |
|
| ||||
| Atypical Antidepressants | 4.47 | 0.76726.048 | 1.78 | 0.308–10.288 |
|
| ||||
| Lamotrigine | 1.17 | 0.366–3.713 | ||
|
| ||||
| Anticonvulsants | 1.45 | 0.33–6.397 | 0.689 | 0.107–4.443 |
|
| ||||
| Lipid Meds | 0.409 | 0.153–1.093 | 0.597 | 0.114–3.131 |
|
| ||||
| Diabetic Meds | 0.0370 | 0.008–0.167 | ||
|
| ||||
| Anticoagulant | 0.422 | 0.052–3.429 | ||
|
| ||||
| NSAIDs | 0.779 | 0.333–1.822 | 0.471 | 0.122–1.819 |
|
| ||||